 
                                  Thijs van Haaps/LinkedIn
                         
                                                                  Oct 29, 2025, 07:38 
                                
                                Thijs van Haaps and Team Show That Andexanet Alfa May Go Beyond Apixaban and Rivaroxaban
RPTH Journal shared a post on LinkedIn:
“New in RPTH!
Thijs van Haaps and team show that Andexanet alfa may go beyond apixaban and rivaroxaban—showing reversal potential for enoxaparin. In both healthy volunteers and bleeding patients, anti-Xa activity fell rapidly and 88% achieved good hemostasis.”
Title: Andexanet Alfa for the Reversal of the Low-Molecular-Weight Heparin Enoxaparin
Authors: Thijs F. van Haaps, Alexander P. Benz, Lizhen Xu, Saskia Middeldorp, John W. Eikelboom, Truman J. Milling, Jr., Mark Crowther, Lisa Holer, Stephan Nolan, Per Ladenvall, Genmin Lu, Michiel Coppens

Read more here.
Stay updated with Hemostasis Today.
- 
                    Oct 31, 2025, 14:17When Stories Save Lives: Reza Shojaei Shares Blood and Plasma Pulse Newest Issue
- 
                    Oct 31, 2025, 13:34Charlotte Pilling Invites You to ''Women in Hematology'' US Focus Meeting
- 
                    Oct 30, 2025, 12:12Laura Ceci Galanos Reflects on WSC 2025
- 
                    Oct 30, 2025, 07:56Vallabh Janardhan: Strokes Affecting Younger Patients
- 
                    Oct 30, 2025, 07:55“Marrow Asleep or Awake?”: William Aird Simplifies Anemia Diagnosis
- 
                    Oct 31, 2025, 13:47Bethany Brown and Colleagues Present Recommendations on DEHP Alternatives
- 
                    Oct 30, 2025, 07:52Haemophilia B - An illustrative review of current challenges and opportunities
- 
                    Oct 30, 2025, 05:14Umberto Pensato on Reperfusion Outcomes in Stroke
- 
                    Oct 29, 2025, 07:39Pablo Corral: Pushing the Limits of LDLc: Emerging Paradigms in CV Risk Reduction
- 
                    Oct 29, 2025, 07:38Thijs van Haaps and Team Show That Andexanet Alfa May Go Beyond Apixaban and Rivaroxaban
- 
                    Oct 29, 2025, 07:31The Use of Artificial Intelligence to Improve Detection of Acute Incidental Pulmonary Emboli - JTH
- 
                    Oct 29, 2025, 07:05Shrinidhi Nathany: AI in Diagnostic Medicine
- 
                    Oct 28, 2025, 07:02Aya Berman: AI Model for Predicting Bacteremia
- 
                    Oct 28, 2025, 06:55The New Era of Genomics, AI and Cell Therapy in Hematology and Infectious Diseases
- 
                    Oct 28, 2025, 06:49Lukas Gaats: Researchers Are Building Reproductive Organoids
- 
                    Oct 31, 2025, 14:41Emilya Huseynova Reflects on AABB 2025
- 
                    Oct 31, 2025, 14:33Cihan Ay Delivers Seminar at McMaster University on Thrombosis Research
- 
                    Oct 31, 2025, 14:25Thomas Reiser Steps Down as ISTH Executive Director After 14+ Years of Leadership
- 
                    Oct 31, 2025, 14:02Murray Adams Reflects on His Week Attending Blood 2025
- 
                    Oct 31, 2025, 13:10Angelique Balguid: World Stroke Day is More Than a Moment — It’s a Movement
Oct 31, 2025, 14:41 
                        
                    Oct 31, 2025, 14:33 
                        
                    Oct 31, 2025, 14:02 
                        
                    Oct 31, 2025, 13:47 
                        
                    Oct 31, 2025, 13:34 
                        
                    Oct 31, 2025, 13:10 
                        
                    Oct 30, 2025, 12:12 
                        
                    